Renin-Angiotensin System Phenotyping as a Guidance Toward Personalized Medicine for ACE Inhibitors: can the Response to ACE Inhibition be Predicted on the Basis of Plasma Renin or ACE?
Purpose & Methods
Not all hypertensive patients respond well to ACE inhibition. Here we determined whether renin-angiotensin system (RAS) phenotyping, i.e., the measurement of renin or ACE, can predict the individual response to RAS blockade, either chronically (enalapril vs. enalapril + candesartan) or acutely (enalapril ± hydrochlorothiazide, HCT).
Chronic enalapril + candesartan induced larger renin rises, but did not lower blood pressure (BP) more than enalapril. Similar observations were made for enalapril + HCT vs. enalapril when given acutely. Baseline renin predicted the peak changes in BP chronically, but not acutely. Baseline ACE levels had no predictive value. Yet, after acute drug intake, the degree of ACE inhibition, like Δrenin, did correlate with ΔBP. Only the relationship with Δrenin remained significant after chronic RAS blockade. Thus, a high degree of ACE inhibition and a steep renin rise associate with larger acute responses to enalapril. However, variation was large, ranging >50 mm Hg for a given degree of ACE inhibition or Δrenin. The same was true for the relationships between Δrenin and ΔBP, and between baseline renin and the maximum reduction in BP in the chronic study.
Our data do not support that RAS phenotyping will help to predict the individual BP response to RAS blockade. Notably, these conclusions were reached in a carefully characterized, homogenous population, and when taking into account the known fluctuations in renin that relate to gender, age, ethnicity, salt intake and diuretic treatment, it seems unlikely that a cut-off renin level can be defined that has predictive value.
KeywordsRenin ACE Enalapril Candesartan Hydrochlorothiazide Phenotyping Therapeutic efficacy
- 2.Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509–19.PubMedCrossRefGoogle Scholar
- 7.Bhatnagar V, O’Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007;25:2082–92.PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Lely AT, Heerspink HJ, Zuurman M, Visser FW, Kocks MJ, Boomsma F, et al. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers. J Hypertens. 2010;28:2414–21.PubMedGoogle Scholar
- 14.Persu A, Lambert M, Deinum J, Cossu M, de Visscher N, Irenge L, et al. A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691 + 1G > A (IVS25 + 1G > A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor. PLoS One. 2013;8:e59537.PubMedCentralPubMedCrossRefGoogle Scholar
- 22.Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844–6.PubMedCrossRefGoogle Scholar
- 26.Gordon K, Balyasnikova IV, Nesterovitch AB, Schwartz DE, Sturrock ED, Danilov SM. Fine epitope mapping of monoclonal antibodies 9B9 and 3G8 to the N domain of angiotensin-converting enzyme (CD143) defines a region involved in regulating angiotensin-converting enzyme dimerization and shedding. Tissue Antigens. 2010;75:136–50.PubMedCrossRefGoogle Scholar
- 31.Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AHJ. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens. 2011;29:2454–61.PubMedCrossRefGoogle Scholar
- 37.Telmisartan Randomised AssessmeNt Study in ACE-iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.Google Scholar
- 41.Boomsma F, de Bruyn JHB, Derkx FHM, Schalekamp MADH. Opposite effects of captopril on angiotensin I-converting enzyme ‘activity’ and ‘concentration’; relation between enzyme inhibition and long-term blood pressure response. Clin Sci (Lond). 1981;60:491–8.Google Scholar
- 42.Kost OA, Balyasnikova IV, Chemodanova EE, Nikolskaya II, Albrecht 2nd RF, Danilov SM. Epitope-dependent blocking of the angiotensin-converting enzyme dimerization by monoclonal antibodies to the N-terminal domain of ACE: possible link of ACE dimerization and shedding from the cell surface. Biochemistry. 2003;42:6965–76.PubMedCrossRefGoogle Scholar